-+ 0.00%
-+ 0.00%
-+ 0.00%

Betta Pharmaceutical announced that the BPI-572270 capsule clinical trial application declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the US FDA. The application number is IND 184065 and is intended for advanced solid tumors. In January 2026, clinical trials of the drug were approved by the State Drug Administration, and it is currently in the phase of dose climbing and dose backfilling.

Zhitongcaijing·10/07/2026 08:25:03
Listen to the news
Betta Pharmaceutical announced that the BPI-572270 capsule clinical trial application declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the US FDA. The application number is IND 184065 and is intended for advanced solid tumors. In January 2026, clinical trials of the drug were approved by the State Drug Administration, and it is currently in the phase of dose climbing and dose backfilling.